摘要
我国是肺结核病高发病率的国家之一。因此有必要在筛选期开展受试者肺结核筛查,并在临床试验长周期随访中做好受试者及研究人员结核防控也尤为重要。本文根据专病特点和Ⅰ期临床实践情况进行经验分享,供行业人员参考。
There is a high incidence of tuberculosis cases in China.Therefore it is necessary to carry out TB screening of subjects during the screening period,and it is also particularly important to do tuberculosis prevention and control in subjects and investigators during the long follow-up of clinical trials.This paper presents the experience based on the characteristics of the specific disease and phase I clinical practice for personnel in the same field to refer to.
作者
方素芳
张菁
吴菊芳
陈晓红
李南洋
杨海静
FANG Su-fang;ZHANG Jing;WU Ju-fang;CHEN Xiao-hong;LI Nan-yang;YANG Hai-jing(Office of Drug Clinical Trials Institution,Teaching Hospital of Fujian Medical University,Fuzhou Pulmonary Hospital,Fuzhou 350008,Fujian Province,China;PhaseⅠClinical Trials Research Center,Huashan Hospital,Fudan University,Shanghai 200040,China)
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2021年第19期2709-2711,共3页
The Chinese Journal of Clinical Pharmacology
关键词
受试者
Ⅰ期临床试验
肺结核
防控
subject
phase I trial
tuberculosis
prevention and control
